New antibiotic pill could heal Flesh-Eating ulcers in weeks
NCT ID NCT06481163
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests a new antibiotic called telacebec for Buruli ulcer, a bacterial skin infection that can cause large open sores. About 200 adults will take telacebec tablets for 14 to 28 days. Researchers will check if the ulcers heal completely within a year without needing surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Telacebec (also known as Q203), an antibiotic tablet
- What this could lead to
- If successful, this could provide a shorter, simpler antibiotic treatment for Buruli ulcer, reducing the need for surgery and lengthy therapy.
- What could go wrong
- This is a mid-stage trial with only 200 participants, so results may not apply to everyone. The treatment may not heal all lesions or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURULI ULCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barwon Health
RECRUITINGGeelong, Victoria, 3220, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Melbourne Hospital
RECRUITINGMelbourne, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.